Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

DCIS: RECAST-Studie zum Duktalkarzinom in situ: Neubewertung der Bedingungen für die Eignung einer aktiven Überwachung als Behandlung

12. November 2026 aktualisiert von: QuantumLeap Healthcare Collaborative

DCIS: RECAST-Studie – Duktales Karzinom in situ: Neubewertung der Bedingungen für die Eignung einer aktiven Überwachung als Behandlung: eine Pilotstudie zur Brustkrebsprävention

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease.

Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

Studienübersicht

Detaillierte Beschreibung

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with Ductal cell Carcinoma In Situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. The current management of most patients with DCIS involves surgical intervention with or without radiation, similar to more aggressive breast cancers. These treatments can come with some significant health effects.The main question this study aims to answer is: to determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance.

Participants will be asked to take one of three investigational study medication (z-Elacestrant, Testosterone + Anastrazole, or Endoxifen) or receive control hormonal therapy (Tamoxifen or an aromatase inhibitor), depending on the treatment to which they have been randomized. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation, participants will have the option to continue on the treatment, with follow up evaluations of Mammogram and MRI at 6 month intervals. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to:

  • Provide blood sample to understand their immune status
  • Provide saliva sample for genetic testing
  • Provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

Participants will be followed annually for 10 years.

Studientyp

Interventionell

Einschreibung (Geschätzt)

400

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Tammy Neseth, MA, CCRP
  • Telefonnummer: +1 (507) 269-8060
  • E-Mail: t.neseth@qlhc.org

Studieren Sie die Kontaktsicherung

  • Name: Sabrina Mayhew, Ph.D. Nursing
  • Telefonnummer: +1 (888) 282-7099
  • E-Mail: s.mayhew@qlhc.org

Studienorte

    • California
      • Berkeley, California, Vereinigte Staaten, 94158
        • Rekrutierung
        • Berkeley Outpatient Center
        • Kontakt:
        • Hauptermittler:
          • Jordan Jackson, MD
        • Kontakt:
      • Duarte, California, Vereinigte Staaten, 91010
        • Rekrutierung
        • City of Hope -Duarte Cancer Center
        • Hauptermittler:
          • Jennifer Tseng, MD
        • Kontakt:
          • Mellissa Henry, RN, MSN, FNP-C
          • Telefonnummer: 626-713-8895
          • E-Mail: mehenry@coh.org
      • Irvine, California, Vereinigte Staaten, 92618
        • Rekrutierung
        • City of Hope - Lennar Foundation Cancer Center
        • Hauptermittler:
          • Jennifer Tseng, MD
        • Kontakt:
          • Mellissa Henry, RN, MSN, FNP-C
          • Telefonnummer: 626-713-8895
          • E-Mail: mehenry@coh.org
      • Los Angeles, California, Vereinigte Staaten, 90095
        • Rekrutierung
        • UCLA
        • Kontakt:
        • Hauptermittler:
          • Mediget Teshome, MD
      • San Francisco, California, Vereinigte Staaten, 94158
        • Rekrutierung
        • UCSF
        • Hauptermittler:
          • Jordan Jackson, MD
        • Kontakt:
      • South Pasadena, California, Vereinigte Staaten, 91030
        • Rekrutierung
        • City of Hope
        • Hauptermittler:
          • Jennifer Tseng, MD
        • Kontakt:
          • Mellissa Henry, RN, MSN, FNP-C
          • Telefonnummer: 626-713-8895
          • E-Mail: mehenry@coh.org
      • Walnut Creek, California, Vereinigte Staaten, 94598
        • Rekrutierung
        • John Muir Health
        • Kontakt:
        • Hauptermittler:
          • Monica Eigelberger, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20010
        • Rekrutierung
        • MedStar Washington Hospital Center
        • Hauptermittler:
          • Marc Boisvert, MD
        • Kontakt:
    • Florida
      • Tampa, Florida, Vereinigte Staaten, 33612
        • Rekrutierung
        • Moffitt Cancer Center
        • Kontakt:
        • Hauptermittler:
          • Laura Kruper, MD
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Rekrutierung
        • Winship Cancer Institute, Emory University
        • Hauptermittler:
          • Clara Farley, MD
        • Kontakt:
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60637
    • Minnesota
      • Maple Grove, Minnesota, Vereinigte Staaten, 55369
        • Rekrutierung
        • Maple Grove Cancer Center
        • Kontakt:
          • Oncology Access Nurse
          • Telefonnummer: 612-624-2620
          • E-Mail: ccinfo@umn.edu
        • Hauptermittler:
          • Jane Hui, MD
      • Minneapolis, Minnesota, Vereinigte Staaten, 55455
        • Rekrutierung
        • University of Minnesota
        • Kontakt:
          • Oncology Access Nurse
          • Telefonnummer: 612-624-2620
          • E-Mail: ccinfo@umn.edu
        • Hauptermittler:
          • Jane Hui, MD
      • Minneapolis, Minnesota, Vereinigte Staaten, 55404
      • Saint Louis Park, Minnesota, Vereinigte Staaten, 55426
      • Saint Paul, Minnesota, Vereinigte Staaten, 55101
    • New Jersey
      • Englewood, New Jersey, Vereinigte Staaten, 07631
        • Rekrutierung
        • Englewood Hospital and Medical Center
        • Kontakt:
        • Hauptermittler:
          • Jennifer Marti, MD
    • New York
      • New York, New York, Vereinigte Staaten, 10011
        • Rekrutierung
        • Mount Sinai Chelsea
        • Hauptermittler:
          • Tara Balija, MD
        • Kontakt:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-Mail: CRSU@mssm.edu
      • New York, New York, Vereinigte Staaten, 10029
        • Rekrutierung
        • Icahn School of Medicine at Mount Sinai
        • Hauptermittler:
          • Tara Balija, MD
        • Kontakt:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-Mail: CRSU@mssm.edu
      • New York, New York, Vereinigte Staaten, 10019
        • Rekrutierung
        • Mount Sinai West
        • Hauptermittler:
          • Tara Balija, MD
        • Kontakt:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-Mail: CRSU@mssm.edu
      • New York, New York, Vereinigte Staaten, 10003
        • Rekrutierung
        • Mount Sinai Union Square
        • Hauptermittler:
          • Tara Balija, MD
        • Kontakt:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-Mail: CRSU@mssm.edu
      • The Bronx, New York, Vereinigte Staaten, 10461
        • Rekrutierung
        • Montefiore Medical Center (Hutchinson Campus Tower 1)
        • Kontakt:
        • Hauptermittler:
          • Sheldon Feldman, MD
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27710
        • Rekrutierung
        • Duke Cancer Institute
        • Kontakt:
        • Hauptermittler:
          • Ton Wang, MD
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27157
    • Pennsylvania
      • Bryn Mawr, Pennsylvania, Vereinigte Staaten, 19010
        • Aktiv, nicht rekrutierend
        • Bryn Mawr Hospital
      • Paoli, Pennsylvania, Vereinigte Staaten, 19301
        • Aktiv, nicht rekrutierend
        • Paoli Hospital
      • Wynnewood, Pennsylvania, Vereinigte Staaten, 19096
        • Aktiv, nicht rekrutierend
        • Lankenau Medical Center
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Rekrutierung
        • Vanderbilt University Medical Center
        • Hauptermittler:
          • Ingrid Meszoely, MD
        • Kontakt:
          • Oncology nursing
          • Telefonnummer: 1-800-811-8480
          • E-Mail: cip@vumc.org
        • Kontakt:
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84112
        • Rekrutierung
        • Huntsman Cancer Institute
        • Hauptermittler:
          • Kirstyn Brownson, MD
        • Kontakt:
    • Virginia
      • Richmond, Virginia, Vereinigte Staaten, 23298
        • Rekrutierung
        • Virginia Commonwealth University
        • Kontakt:
        • Hauptermittler:
          • Kandace McGuire, MD
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98109
        • Rekrutierung
        • Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)
        • Hauptermittler:
          • Sara Javid, MD
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

A. Female, at least 18 years old

B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion

  • Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial.

C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial

D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation.

E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation.

F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant

G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment

H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent

I. Willingness and ability to provide tumor samples for research

Exclusion Criteria:

A. Pregnant or actively breastfeeding women

B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history

C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer

D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND

E. Ongoing treatment for DCIS other than what is specified in this protocol

F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements

G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures

*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay)

H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment

I. Participants with substantial MRI artifacts (e.g., related to localizer sequences, cardiac devices such as pacemakers, or other hardware) that render the lesion non-evaluable.

J. Severe allergy or reaction history to MRI contrast.

K. Participants currently undergoing or who have received treatment for another malignancy within the previous 6 months.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: chemoprevention therapy per investigator choice

For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).

For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3X per week orally.

For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.

There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years.

For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).

For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.

For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally

For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.

For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.

Experimental: Testosterone + Anastrazole (T+Ai)

White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.

Andere Namen:
  • T+Ai
Experimental: Elacestrant

Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.

Experimental: Endoxifen

(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Patients remaining on active surveillance at 7 months
Zeitfenster: 7 months

Fraction of patients remaining on active surveillance at 7 months compared to control

7 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 6 months compared to control
Zeitfenster: 6 months

Fraction of patients categorized as low risk by MRI after 6 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background)

6 months
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 3 months compared to control
Zeitfenster: 3 months

Fraction of patients categorized as low risk by MRI after 3 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background)

3 months
Associate rate of progression to Invasive Ductal Carcinoma (IDC) with risk categorization after 6 months of treatment at 3 years
Zeitfenster: 3 years

Correlation of low-risk categorization at 6 months with subsequent rate of Invasive Ductal Cell Carcinoma progression at 3 years

3 years
To assess the QoL impact of novel endocrine therapy compared to tamoxifen or Aromatase inhibitor (Ai) at standard or low dose using PROMIS and the FACT-ES and FACT-GP5 composite score compared to control
Zeitfenster: 6 months

Fraction of patients experiencing Minimum Important Difference in overall QOL measured by PROP-R statistics (PROMIS) and FACT-ES (functional assessment of cancer therapy- endocrine symptoms) and FACT-GP5, a quality of life (QoL) assessment)

6 months
For those with an identified lesion on MRI imaging, determine whether neoadjuvant endocrine therapy decreases lesion volume (qualitative, quantitative) and whether that corresponds to the biologic type of Ductal cell carcinoma In Situ (DCIS)
Zeitfenster: 6 months

Rate of reduction in focal lesions (mass and non-mass enhancement (NME) at 6 months and Rate of reduction in focal lesions using automated Functional Tumor Volume

6 months
To determine whether neoadjuvant endocrine therapy decreases automated background parenchymal enhancement (BPE and automated MRI density compared to Ai and Tamoxifen
Zeitfenster: 6 months

% with contralateral reduction in qualitative and automated BPE and % reduction in contralateral breast density

6 months
Determine adherence to active surveillance protocol
Zeitfenster: 5 years

Time to discontinuation of therapy (Tolerability of therapy) will be measured, and Adherence rates on each regimen, as well as PROP-R, FACT-ES and FACT-GP5 score on each regimen will be measured. These assessments will be combined to evaluate efficacy and toxicity using a novel clinical benefit index.

5 years
Change in artificial intelligence predicted risk based on mammography
Zeitfenster: 5 years

Correlation of BPE change with agent and compare to quantitative imaging density

5 years

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Assess Germ Line polygenic risk: assess correlation of detectable mutations with endocrine response and qualification for active surveillance at 7 months
Zeitfenster: 7 months

evaluate influence of polygenic risk on endocrine response and suitability for Active Surveillance

7 months
To evaluate outcomes stratified by immune and molecular subtype based upon multiplex immuno histochemistry (IHC) clustering analysis, and RPS expression array profiling
Zeitfenster: 7 months

Response stratified by multiplex immune staining for Human Epidermal growth factor receptor-2 (HER2) isoforms and Response Predictive Subtypes (RPS)

7 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Laura Esserman, MD, MBA, University of California, San Fancisco - Department of Surgery
  • Hauptermittler: (Co-PI) Kelly Hewitt, MD, FACS, Huntsman Cancer Institute at the University of Utah

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. Februar 2024

Primärer Abschluss (Geschätzt)

1. November 2028

Studienabschluss (Geschätzt)

1. November 2033

Studienanmeldedaten

Zuerst eingereicht

22. September 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. Oktober 2023

Zuerst gepostet (Tatsächlich)

10. Oktober 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren